SCHEMBL14450220

SCHEMBL14450220

Cc1ccc(N2CC[C@@H](N(C)C)C2)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR1 P21462 2/20 0.43
FPR2 P25090 2/20 0.43
ACACB O00763 1/20 0.43
KCNH2 Q12809 1/20 0.40
SCN5A Q14524 1/20 0.40
PIM1 P11309 1/20 0.39
PIM3 Q86V86 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
MAPK8 P45983 1/20 0.38
MAPK10 P53779 1/20 0.38
BTK Q06187 1/20 0.38
MRGPRX2 Q96LB1 1/20 0.38
CHEK2 O96017 3/20 0.38
WDR5 P61964 3/20 0.37
PDK2 Q15119 1/20 0.37
LCK P06239 2/20 0.37
KDR P35968 2/20 0.37
TEK Q02763 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13419443 0.91 KCNH2 (0.46) ACACBKCNH2SCN5APDK2PIK3CD
SCHEMBL15759208 0.85 ACACB (0.41) FPR1FPR2ACACBWDR5PDK2
SCHEMBL4259153 0.84 ALDH1A1 (0.48) FPR1FPR2PIM1PIM3PIM2
SCHEMBL189139 0.84 ALDH1A1 (0.48) FPR1FPR2PIM1PIM3PIM2
SCHEMBL22164691 0.84 ALDH1A1 (0.48) FPR1FPR2PIM1PIM3PIM2
SCHEMBL10203188 0.82 FPR1 (0.41) FPR1FPR2PIM1PIM3PIM2
SCHEMBL1749267 0.82 FPR1 (0.48) FPR1FPR2PIM1PIM3PIM2
SCHEMBL1749264 0.82 FPR1 (0.48) FPR1FPR2PIM1PIM3PIM2
SCHEMBL10263772 0.82 FPR1 (0.41) FPR1FPR2KCNH2PIM1PIM3
SCHEMBL15759212 0.81 MEN1 (0.43) ACACBKCNH2SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9156820-B2 Polycyclic heteroaryl substituted triazoles useful as axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-10-13 US disclosed
US-20140323490-A1 POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2014-10-30 US disclosed
US-8741898-B2 Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2014-06-03 US disclosed
WO-2007093363-A1 NOVEL AZACYCLY-SUBSTITUTED ARYLTHIENOPYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS SANOFI-AVENTIS (DE) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323490-A1 POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS AXL, TYRO3, ERBB3 FPR1 869/4885FPR2 1007/4885ACACB 3665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.